Regeneron to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2020

Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) will report its Q2 2020 financial and operating results on August 5, 2020, before U.S. markets open. A conference call and webcast will be held at 8:30 AM ET on the same day. Investors can access the call by dialing (888) 660-6127 (U.S.) or (973) 890-8355 (International). Regeneron is a biotechnology leader focused on inventing medicines for serious diseases, with a robust pipeline developed through their proprietary VelociSuite® technologies. For more information, visit www.regeneron.com.

TARRYTOWN, N.Y., July 8, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2020 financial and operating results on Wednesday, August 5, 2020, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Conference Call Information
To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International).  A link to the webcast may be accessed from the 'Investors and Media' page of Regeneron's website at http://investor.regeneron.com/events.cfm.  A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. 

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite^® technologies, such as VelocImmune^® which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:
Investor Relations
Justin Holko
914.847.7786
justin.holko@regeneron.com

Corporate Communications
Hala Mirza
914.847.3422
hala.mirza@regeneron.com 

View original content:http://www.prnewswire.com/news-releases/regeneron-to-report-second-quarter-2020-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-5-2020-301089994.html

SOURCE Regeneron Pharmaceuticals, Inc.

FAQ

When will Regeneron report its Q2 2020 results?

Regeneron will report its Q2 2020 financial results on August 5, 2020.

What time is Regeneron's conference call on August 5, 2020?

The conference call will take place at 8:30 AM Eastern Time on August 5, 2020.

How can I access Regeneron's conference call?

You can access the conference call by dialing (888) 660-6127 for U.S. callers or (973) 890-8355 for international callers.

Where can I find the webcast for Regeneron's results?

The webcast can be accessed from the 'Investors and Media' page on Regeneron's website.

What is Regeneron known for?

Regeneron is known for inventing life-transforming medicines for serious diseases and has developed several FDA-approved treatments.